Home
Conditions
Lymphoma

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

1,466 public trials 175 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma trial results

Active, Not Recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

NCT02690545

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

View Trial Details

Active, Not Recruiting

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04478318

Conditions: Fluorodeoxyglucose, Hemic and Lymphatic Diseases, Immune System Diseases, +23 more
Locations: University of California Davis Sacramento, California, United States

View Trial Details

Active, Not Recruiting

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

NCT01446133

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +14 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

NCT03502733

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
Locations: National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States

National Institutes of Health Clinical Center Bethesda, Maryland, United States

UT MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390

Conditions: Acute Lymphocytic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, Not Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT03602157

Conditions: Cutaneous Anaplastic Large Cell Lymphoma, Cutaneous Lymphoma, Cutaneous T Cell Lymphoma, +15 more
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

View Trial Details

Active, Not Recruiting

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: Beijing Cancer Hospital Beijing, China

Peking University Third Hospital Beijing, China

The First Hospital of Jilin University Changchun, China

West China Hospital, Sichuan University Chengdu, China

View all 16 locations

View Trial Details

Active, Not Recruiting

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +7 more
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

Wake Forest University Winston-Salem, North Carolina, United States

View Trial Details

Active, Not Recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

Alaska Women's Cancer Care Anchorage, Alaska, United States

Anchorage Oncology Centre Anchorage, Alaska, United States

Katmai Oncology Group Anchorage, Alaska, United States

View all 418 locations

View Trial Details

Lymphoma

Lymphoma trial results

Related conditions